Positive News SentimentPositive NewsNASDAQ:IFRX InflaRx (IFRX) Stock Price, News & Analysis $1.45 +0.01 (+0.69%) (As of 09/18/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get InflaRx alerts: Email Address About InflaRx Stock (NASDAQ:IFRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InflaRx alerts:Sign Up Key Stats Today's Range$1.42▼$1.4650-Day Range$1.34▼$1.6852-Week Range$1.14▼$3.66Volume28,313 shsAverage Volume169,628 shsMarket Capitalization$85.38 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingStrong Buy Company OverviewInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Read More… 44-year Wall Street Vet: “Permanent devastation is coming to America” (Ad)After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.The information in this video is crucially valuable. InflaRx Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 70th PercentileInflaRx scored higher than 70% of companies evaluated by MarketBeat, and ranked 339th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingInflaRx has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInflaRx has only been the subject of 1 research reports in the past 90 days.Read more about InflaRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for InflaRx are expected to decrease in the coming year, from ($0.98) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InflaRx is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InflaRx is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInflaRx has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about InflaRx's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.37% of the outstanding shares of InflaRx have been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently decreased by 3.60%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInflaRx does not currently pay a dividend.Dividend GrowthInflaRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.37% of the outstanding shares of InflaRx have been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently decreased by 3.60%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentInflaRx has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.Search Interest1 people have searched for IFRX on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InflaRx insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InflaRx's insider trading history. Receive IFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Stock News HeadlinesInflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human DiseasesSeptember 3, 2024 | globenewswire.comInflaRx Announces Participation in September Investor EventsAugust 27, 2024 | globenewswire.com44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.September 18, 2024 | InvestorPlace (Ad)IFRX Sep 2024 2.500 call (IFRX240920C00002500)August 18, 2024 | finance.yahoo.comInflaRx Buy Rating Backed by Promising Drug Prospects and Financial StabilityAugust 13, 2024 | markets.businessinsider.comInflaRx N.V.: InflaRx Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | finanznachrichten.deInflaRx Buy Rating Affirmed: Financial Stability and Gohibic’s Market PotentialAugust 8, 2024 | markets.businessinsider.comIFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q2 2024August 8, 2024 | markets.businessinsider.comSee More Headlines IFRX Stock Analysis - Frequently Asked Questions How have IFRX shares performed this year? InflaRx's stock was trading at $1.63 at the beginning of 2024. Since then, IFRX stock has decreased by 11.0% and is now trading at $1.45. View the best growth stocks for 2024 here. How were InflaRx's earnings last quarter? InflaRx (NASDAQ:IFRX) released its earnings results on Thursday, August, 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.05. The business earned $0.01 million during the quarter, compared to the consensus estimate of $0.04 million. InflaRx had a negative trailing twelve-month return on equity of 47.03% and a negative net margin of 44,046.09%. When did InflaRx IPO? InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are InflaRx's major shareholders? Top institutional shareholders of InflaRx include Marshall Wace LLP (0.06%). How do I buy shares of InflaRx? Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of InflaRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK) and Capricor Therapeutics (CAPR). Company Calendar Last Earnings8/08/2024Today9/18/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IFRX CUSIPN/A CIK1708688 Webwww.inflarx.de Phone493641508180Fax49-36-4150-8181Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$19.00 Low Stock Price Target$8.00 Potential Upside/Downside+831.0%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,180,000.00 Net Margins-44,046.09% Pretax Margin-44,115.65% Return on Equity-47.03% Return on Assets-41.56% Debt Debt-to-Equity RatioN/A Current Ratio8.91 Quick Ratio7.97 Sales & Book Value Annual Sales$105,483.00 Price / Sales809.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.89 per share Price / Book0.77Miscellaneous Outstanding Shares58,883,000Free Float49,285,000Market Cap$85.38 million OptionableOptionable Beta1.57 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:IFRX) was last updated on 9/18/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.